Spots Global Cancer Trial Database for Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Official Title: Expanded Access Use of Adagrasib (MRTX849) for the Treatment of Patients With Advanced Solid Tumors With a KRAS G12C Mutation
Study ID: NCT05162443
Interventions
Study Description
Brief Summary: The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
California Pacific Medical Center, San Francisco, California, United States
Providence Medical Group Santa Rosa - Cancer Center, Santa Rosa, California, United States
Hartford Hospital, Hartford, Connecticut, United States
Piedmont Cancer Institute, Atlanta, Georgia, United States
Mayo Clinic - Rochester, Rochester, Minnesota, United States
Renown Health, Reno, Nevada, United States
Lehigh Valley Cancer Institute, Allentown, Pennsylvania, United States
Lumi Research, Kingwood, Texas, United States
Virginia Cancer Institute, Richmond, Virginia, United States
Seattle Integrative Cancer Center, Renton, Washington, United States
Swedish Cancer Institute, Seattle, Washington, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
